A Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate Cancer

Inclusion Criteria 1. understanding of this study and voluntarily signs the informed consent form; 2. Aged ≥ 18 years; 3. Expected survival time of at least 3 months; 4. non-metastatic CRPC (nmCRPC) (local recurrence) or metastatic CRPC (mCRPC)； 5. continue GnRH analog therapy； 6. at least one evaluable lesion per RECIST 1.1; 7. Has received at least one type of novel endocrine therapy； 8. PSMA positive expression rate \> 10%; 9. Eastern Cooperative Oncology Group (ECOG) 0-1; 10. Well organ function 11. Left Ventricular Ejection Fraction (LVEF) \> 50%; 12. Oxygen saturation \> 92% without oxygen supplementation; 13. agree to use effective contraceptive measures Exclusion Criteria 1. Presence of brain metastasis; 2. Organ transplantation or pending organ transplantation; 3. Uncontrolled large-volume serous cavity effusions； 4. A history of autoimmune diseases； 5. A history of receiving other cell therapies or genetically modified cell therapies (e.g., TCR-T therapy, CAR-T therapy); 6. A history of receiving any PSMA-targeted therapy; 7. Requirement for steroid therapy (except for physiological replacement therapy); 8. A history of receiving immunotherapies; 9. A history of clinically significant central nervous system (CNS) diseases (either past or present at screening); (12) A history of other untreated malignant tumors; (13) Participants with severe cardiovascular diseases; (14) Active infectious diseases; (15) Active hepatitis B or hepatitis C virus infection; (16) Active Epstein-Barr virus (EBV) or cytomegalovirus (CMV) infection (17) Intolerance or allergy to cyclophosphamide or fludarabine chemotherapeutic drugs; (18) No accessible injection sites; (19) Assessment by the investigator that the participant is unsuitable for participation in this clinical study.